Because of the inaccuracy and low efficiencies of traditional treatment, such as surgery, chemotherapy, and radiotherapy, in recent years, RDC (Radionuclide Drug Conjugate), with targeted diagnosis and imaging, has been widely noticed and studied in recent years.

The targeting biomolecules in RDC could be antibodies, small molecules, and peptides, in which antibodies are most commonly used, also name RAC (Radionuclide Antibody Conjugate).

Rdcthera, adapting the advanced antibody discovery technology, is professional at antibody discovery, screening, and synthesis.

Learn more: rdcthera antibody development